Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Morita M, Ono A, Sekikawa M, Doshita K, Miura K, Kodama H, Yabe M, Morikawa N, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Kenmotsu H, Naito T, Murakami H, Isaka M, Ohde Y, Takahashi T. Morita M, et al. Among authors: murakami h. Cancer Rep (Hoboken). 2024 Sep;7(9):e70004. doi: 10.1002/cnr2.70004. Cancer Rep (Hoboken). 2024. PMID: 39245880 Free PMC article.
Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.
Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S, Murakami H, Takeshima Y, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y. Ishikawa N, et al. Among authors: murakami h. Cancer Res. 2005 Oct 15;65(20):9176-84. doi: 10.1158/0008-5472.CAN-05-1556. Cancer Res. 2005. PMID: 16230376
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T, Yamada Y, Tamura T. Yamamoto N, et al. Among authors: murakami h. Cancer Chemother Pharmacol. 2008 Mar;61(3):489-96. doi: 10.1007/s00280-007-0494-8. Epub 2007 May 5. Cancer Chemother Pharmacol. 2008. PMID: 17483950 Clinical Trial.
Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study.
Shukuya T, Takahashi T, Tamiya A, Ono A, Igawa S, Tsuya A, Nakamura Y, Murakami H, Naito T, Kaira K, Endo M, Yamamoto N. Shukuya T, et al. Among authors: murakami h. Jpn J Clin Oncol. 2009 Mar;39(3):158-62. doi: 10.1093/jjco/hyn147. Epub 2009 Jan 12. Jpn J Clin Oncol. 2009. PMID: 19139038
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
Yamamoto N, Tamura T, Yamamoto N, Yamada K, Yamada Y, Nokihara H, Fujiwara Y, Takahashi T, Murakami H, Boku N, Yamazaki K, Puchalski TA, Shin E. Yamamoto N, et al. Among authors: murakami h. Cancer Chemother Pharmacol. 2009 Nov;64(6):1165-72. doi: 10.1007/s00280-009-0979-8. Epub 2009 Mar 24. Cancer Chemother Pharmacol. 2009. PMID: 19308410 Clinical Trial.
3,292 results